scholarly journals Effects of Serum Concentrations of Disopyramide and Its Metabolite Mono-N-dealkyldisopyramide on the Anticholinergic Side Effects Associated with Disopyramide

2008 ◽  
Vol 31 (7) ◽  
pp. 1368-1370 ◽  
Author(s):  
Yoshimasa Tsuchishita ◽  
Kyoko Fukumoto ◽  
Masaaki Kusumoto ◽  
Kazuyuki Ueno
Keyword(s):  
Side Effects ◽  
Serum Concentrations ◽  
Anticholinergic Side Effects

MIANSERIN AND MAPROTILINE BY THEIR ANTICHOLINERGIC SIDE EFFECTS

1992 ◽  
Vol 15 ◽  
pp. 419B ◽  
Author(s):  
T. KALELIOGLU ◽  
N. ERADAMLAR ◽  
E. KANTARCI ◽  
A. VERIMLI ◽  
L. ALPKAN ◽  
...  
Keyword(s):  
Side Effects ◽  
Anticholinergic Side Effects

scholarly journals Anticholinergic side effects

2015 ◽  
Vol 16 (2) ◽  
pp. 117-118 ◽  
Author(s):  
Koji Kamiya ◽  
Yasunari Kamiya ◽  
Haruo Niwa
Keyword(s):  
Side Effects ◽  
Anticholinergic Side Effects

Cannabidiol Interacts Significantly with Everolimus—Report of a Patient with Tuberous Sclerosis Complex

2019 ◽  
Vol 50 (06) ◽  
pp. 400-403 ◽  
Author(s):  
Adelheid Wiemer-Kruel ◽  
Brigitte Stiller ◽  
Thomas Bast
Keyword(s):  
Side Effects ◽  
Tuberous Sclerosis Complex ◽  
Cardiac Rhythm ◽  
Seizure Activity ◽  
Trough Level ◽  
Focal Epilepsy ◽  
Serum Concentrations ◽  
Daily Dose ◽  
Life Threatening ◽  
Trough Levels

A 6.5-year-old female patient with a TSC2 mutation had been given everolimus (EVE) for 3 years for pharmacoresistant focal epilepsy and for life-threatening, severe ventricular dysrhythmia. EVE had been started with daily dose of 0.15 mg/kg/day and was increased up to 0.6 mg/kg/day. Target blood trough levels of around 9 µg/L had been documented. Although EVE therapy revealed no effect on seizure activity, cardiac rhythm normalized completely. Thus, EVE was reduced to a dose of 0.3 mg/kg/day leading to stable blood trough levels of 4 to 5 µg/L. Due to refractory tonic seizures with a frequency of 1 to 4 per day, we initiated cannabidiol (CBD) treatment, raising it to a daily dose of 200 mg. After 6 weeks, the EVE blood trough levels rose to 12.0 µg/L. Although we halved the EVE dose, her EVE blood trough level continued increasing up to 16.0 µg/L.The CBD dose was increased to 500 mg/day (20.4 g/kg/day), but EEG parameters and seizures failed to respond. Serum concentrations of EVE were unstable under the co-medication with CBD. Depending on the CBD dose, they varied between 1.7 and 12.3 µg/L, while EVE was always administered at the same dose.Although never before reported, CBD and EVE appear to interact, due to the metabolic pathway through CYP 450 3A4. Although we detected no side effects in our patient, we strongly recommend drug monitoring using the combination of CBD with EVE to prevent harmful overdosing.

Pulmonary embolism from persistent dilatation of the bladder secondary to anticholinergic side effects

2009 ◽  
Vol 31 (2) ◽  
pp. 187-189 ◽  
Author(s):  
Masanobu Ito ◽  
Kotaro Hatta ◽  
Koichi Miyakawa ◽  
Heii Arai
Keyword(s):  
Pulmonary Embolism ◽  
Side Effects ◽  
Anticholinergic Side Effects

scholarly journals Making Sense of Lamotrigine Serum Levels

2005 ◽  
Vol 5 (3) ◽  
pp. 115-115 ◽  
Author(s):  
Bassel W. Abou-Khalil
Keyword(s):  
Side Effects ◽  
Serum Levels ◽  
Target Range ◽  
Seizure Freedom ◽  
Serum Concentrations ◽  
Making Sense ◽  
Patients With Epilepsy ◽  
Concurrent Medication ◽  
Dose Change ◽  
Initial Target

Correlating Lamotrigine Serum Concentrations with Tolerability in Patients with Epilepsy Hirsch LJ, Weintraub D, Du Y, Buchsbaum R, Spencer HT, Hager M, Straka T, Bazil CW, Adams DJ, Resor SR Jr, Morrell MJ Neurology 2004;63:1022–1026 Objective To correlate lamotrigine (LTG) serum concentrations (levels) with tolerability in patients with epilepsy. Methods The charts of 811 outpatients with epilepsy who had received LTG and were seen at the Columbia Comprehensive Epilepsy Center after January 1, 2000, were reviewed. Data gathered included levels, dosage, duration of use, concomitant antiepileptic drugs (AEDs), clinical toxicity, specific side effects, and efficacy. Rates of toxicity, specific side effects, and efficacy were calculated and correlated with serum levels. Results In total, 3,731 LTG levels were recorded. A regimen was categorized as toxic if the patient experienced side effects that led to a dosage change or discontinuation of LTG. Of 3,919 AED regimens, 9.4% were toxic, and 30.7% of patients had at least one toxic regimen. Toxicity increased with increasing LTG levels ( P < 0.0001): With levels less than 5.0 μg/mL, 7% of patients were toxic; with levels of 5 to 10 μg/mL, 14%; with 10 to 15 μg/mL, 24%; with 15 to 20 μg/mL, 34%; and with more than 20 μg/mL, 59%. The correlation between levels and tolerability was independent of concurrent medication. Increasing efficacy, as measured by seizure freedom for a 6-month period, occurred up to levels of more than 20 μg/mL. Conclusions A correlation exists between LTG serum level and tolerability, independent of the use of other AEDs. Adverse effects requiring a dose change are uncommon with the most frequently encountered LTG concentrations (<10 μg/mL) and occur in only 7.4% of patients at levels obtained during the majority of clinical trials (<5 μg/mL). An initial target range of 1.5 to 10 μg/mL is suggested, although higher levels, up to more than 20 μg/mL, are often tolerated and can lead to additional efficacy in refractory patients.

Femoxetine and Eye FunctionA Study of Possible Anticholinergic Side Effects

1985 ◽  
Vol 18 (03) ◽  
pp. 231-234 ◽  
Author(s):  
K. Jeppesen ◽  
H. Fledelius
Keyword(s):  
Side Effects ◽  
Anticholinergic Side Effects

Deaths in the Central Mental Hospital

1989 ◽  
Vol 6 (2) ◽  
pp. 144-147 ◽  
Author(s):  
Marjorie Stokes ◽  
Art O'Connor
Keyword(s):  
Side Effects ◽  
Suicide Rate ◽  
Patient Population ◽  
Death Rate ◽  
Mental Hospital ◽  
Young Patients ◽  
Admission Rate ◽  
Total Period ◽  
Anticholinergic Side Effects

AbstractAll deaths occurring in the in-patient population of the Central Mental Hospital during the period 1963 to 1987 inclusive were examined. The death rate during the total period was 11.7 per 1,000 admissions. The suicide rate during the total period was 3.9 per 1,000 admissions – there had been no suicides during the most recent five year period. Although the admission rate has been rising since the mid-1970s, the death rate over the last fifteen years has remained stable.Many of the deaths prior to 1970 were in elderly long stay patients who died from natural causes. Five deaths in young patients are described separately – in two of these anticholinergic side effects of medication may have contibuted to the deaths. Seven suicides occcuring during the study period are described separately – four of these occurred in the months soon after admission.

Feasibility of Measuring 5-Fluorouracil Catabolic Potential by Oral Loading

2005 ◽  
Vol 33 (5) ◽  
pp. 501-506 ◽  
Author(s):  
S Watabe ◽  
H Sengoku ◽  
K Kawai ◽  
M Matsuda ◽  
K Sakamoto ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Side Effects ◽  
Load Test ◽  
Serum Concentrations ◽  
Optimum Conditions ◽  
Continuous Administration ◽  
Individual Variations ◽  
Before And After ◽  
Catabolic Potential ◽  
Simple Evaluation

The efficacy of 5-fluorouracil (5-FU) treatment and the incidence of adverse events differ among patients and depend to some extent on individual variations in drug catabolism. This feasibility study aimed to determine the optimum conditions for a 5-FU oral load test, which would allow the simple evaluation of individual differences in 5-FU catabolism. Patients with colon cancer were given oral 5-FU (200 mg/day) for 3 days ( n = 36) or a single 100 mg dose ( n = 14). Serum concentrations of uracil, dihydrouracil, 5-FU and 5-fluoro-5, 6-dihydrouracil were measured before and after 5-FU administration. The results suggested that a decline in 5-FU metabolism was associated with continuous administration and increasing age. We conclude that a continuous load of 5-FU is necessary in order to predict the efficacy and side-effects of the drug. The 3-day regimen, with its ease of administration, merits further study to assess its possible clinical application.

Sign in / Sign up

Export Citation Format

Share Document